Multiplex targeted high-throughput sequencing in a series of 352 patients with congenital limb malformations.


Journal

Human mutation
ISSN: 1098-1004
Titre abrégé: Hum Mutat
Pays: United States
ID NLM: 9215429

Informations de publication

Date de publication:
01 2020
Historique:
received: 01 07 2019
revised: 31 08 2019
accepted: 05 09 2019
pubmed: 11 9 2019
medline: 20 5 2021
entrez: 11 9 2019
Statut: ppublish

Résumé

Congenital limb malformations (CLM) comprise many conditions affecting limbs and more than 150 associated genes have been reported. Due to this large heterogeneity, a high proportion of patients remains without a molecular diagnosis. In the last two decades, advances in high throughput sequencing have allowed new methodological strategies in clinical practice. Herein, we report the screening of 52 genes/regulatory sequences by multiplex high-throughput targeted sequencing, in a series of 352 patients affected with various CLM, over a 3-year period of time. Patients underwent a clinical triage by expert geneticists in CLM. A definitive diagnosis was achieved in 35.2% of patients, the yield varying considerably, depending on the phenotype. We identified 112 single nucleotide variants and 26 copy-number variations, of which 52 are novel pathogenic or likely pathogenic variants. In 6% of patients, variants of uncertain significance have been found in good candidate genes. We showed that multiplex targeted high-throughput sequencing works as an efficient and cost-effective tool in clinical practice for molecular diagnosis of congenital limb malformations. Careful clinical evaluation of patients may maximize the yield of CLM panel testing.

Identifiants

pubmed: 31502745
doi: 10.1002/humu.23912
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

222-239

Informations de copyright

© 2019 Wiley Periodicals, Inc.

Auteurs

Anne-Sophie Jourdain (AS)

Service de Biochimie et Biologie Moléculaire, CHU Lille, Lille, France.
EA7364 RADEME, Univ. Lille, Lille, France.

Florence Petit (F)

EA7364 RADEME, Univ. Lille, Lille, France.
Clinique de Génétique Guy Fontaine, CHU Lille, Lille, France.

Marie-Françoise Odou (MF)

Service de Biochimie et Biologie Moléculaire, CHU Lille, Lille, France.
Faculty of Pharmacy, UMR995, LIRIC (Lille Inflammation Research International Center), University of Lille, Lille, France.

Malika Balduyck (M)

Service de Biochimie et Biologie Moléculaire, CHU Lille, Lille, France.
EA7364 RADEME, Univ. Lille, Lille, France.

Perrine Brunelle (P)

Service de Biochimie et Biologie Moléculaire, CHU Lille, Lille, France.
Clinique de Génétique Guy Fontaine, CHU Lille, Lille, France.

William Dufour (W)

Clinique de Génétique Guy Fontaine, CHU Lille, Lille, France.

Simon Boussion (S)

Clinique de Génétique Guy Fontaine, CHU Lille, Lille, France.

Elise Brischoux-Boucher (E)

Centre de génétique humaine CHU, Université de Franche-Comté, Besançon, France.

Cindy Colson (C)

Centre de Génétique, CHU Caen, Caen, France.

Anne Dieux (A)

Clinique de Génétique Guy Fontaine, CHU Lille, Lille, France.

Marion Gérard (M)

Centre de Génétique, CHU Caen, Caen, France.

Jamal Ghoumid (J)

EA7364 RADEME, Univ. Lille, Lille, France.
Clinique de Génétique Guy Fontaine, CHU Lille, Lille, France.

Fabienne Giuliano (F)

Service de Médecine Génétique, CHUV Lausanne, Lausanne, Switzerland.

Alice Goldenberg (A)

Service de Génétique Médicale, CHU Rouen, Rouen, France.

Philippe Khau Van Kien (P)

UF de Génétique Médicale et Cytogénétique, CHU Nîmes, Nîmes, France.

Daphné Lehalle (D)

Reference Center for Developmental Anomalies, Department of Medical Genetics, Dijon University Hospital, Dijon, France.

Gilles Morin (G)

Centre d'activité de Génétique et d'Oncogénétique, CHU Amiens Picardie, Amiens, France.

Sébastien Moutton (S)

Reference Center for Developmental Anomalies, Department of Medical Genetics, Dijon University Hospital, Dijon, France.

Thomas Smol (T)

EA7364 RADEME, Univ. Lille, Lille, France.
Institut de Génétique Médicale, CHU Lille, Lille, France.

Clémence Vanlerberghe (C)

EA7364 RADEME, Univ. Lille, Lille, France.
Clinique de Génétique Guy Fontaine, CHU Lille, Lille, France.

Sylvie Manouvrier-Hanu (S)

EA7364 RADEME, Univ. Lille, Lille, France.
Clinique de Génétique Guy Fontaine, CHU Lille, Lille, France.

Fabienne Escande (F)

Service de Biochimie et Biologie Moléculaire, CHU Lille, Lille, France.
EA7364 RADEME, Univ. Lille, Lille, France.

Articles similaires

Genome, Chloroplast Phylogeny Genetic Markers Base Composition High-Throughput Nucleotide Sequencing

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C

Classifications MeSH